secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001193125-22-301136
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Lifesciences CEO Mike Mussallem retiring May 2023; Bernard Zovighian to become CEO
--------------------------------------------------------------------------------

- CEO Mussallem (70) to retire at May 11, 2023 annual meeting; will become non-executive chairman.
- Bernard Zovighian named President effective Jan 1, 2023, then CEO on May 11, 2023.
- Larry Wood expands to corporate VP and group president for TAVR and Surgical Structural Heart.
- Daveen Chopra to succeed Zovighian as head of Transcatheter Mitral & Tricuspid Therapies (TMTT).
- Zovighian base salary increased to $800k, incentive target $800k; Wood to $750k each.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/d423822d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-301136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer